vatalanib has been researched along with pd 173074 in 2 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (pd 173074) | Trials (pd 173074) | Recent Studies (post-2010) (pd 173074) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 160 | 0 | 106 |
| Protein | Taxonomy | vatalanib (IC50) | pd 173074 (IC50) |
|---|---|---|---|
| Platelet-derived growth factor receptor beta | Mus musculus (house mouse) | 0.028 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.0217 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.028 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.19 | |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | 0.013 | |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | 0.5337 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.0268 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.19 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.1325 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Batey, MA; de Brito, LR; Hall, AG; Irving, JA; Jackson, G; Leung, HY; Maitland, H; Newell, DR; Squires, MS; Zhao, Y | 1 |
2 other study(ies) available for vatalanib and pd 173074
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Phthalazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sunitinib; Xenograft Model Antitumor Assays | 2011 |